NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

antibody

c-Abl Polyclonal Antibody

PA5-39688

100 µg

US 413.00

polyclonal

domestic rabbit

nonconjugated

human, mouse, rat

western blot, immunohistochemistry, immunohistochemistry - paraffin section

c-Abl Polyclonal Antibody

PA5-39688

100 µg

US 413.00

Polyclonal

Antigen affinity chromatography

Rabbit

Human, Mouse, Rat

Immunohistochemistry (Paraffin): 1:50-1:100, Western Blot: 1:500-1:1,000

Human, Mouse, Rat

IgG

-20°C

c-Abl (Abelson murine leukemia viral oncogene homolog 1, ABL1) is a 140 kDa proto-oncogene member of the Src family of non-receptor tyrosine kinases. c-Abl has been implicated in processes of cell differentiation, cell division, cell adhesion, and stress response. Activity of c-Abl protein is negatively regulated by its SH3 domain, and deletion of the SH3 domain turns c-Abl into an oncogene. The t(9;22) translocation results in the head-to-tail fusion of the BCR and c-Abl genes present in many cases of chronic myelogeneous leukemia. The DNA-binding activity of the ubiquitously expressed ABL1 tyrosine kinase is regulated by CDC2-mediated phosphorylation, suggesting a cell cycle function for c-Abl. In chronic myelogenous leukemia and a subset of acute lymphoblastic leukemias, the c-Abl proto oncogene undergoes a (9;22) chromosomal translocation producing a novel rearranged chromosome (the Philadelphia chromosome) As the result of the fusion of c-Abl sequences from chromosome 9 to the Bcr gene on chromosome 22. The molecular consequence of this translocation is the generation of a chimeric Bcr/Abl mRNA encoding activated Abl protein tyrosine kinase. The c-Abl oncogene was initially identified as the viral transforming gene of Abelson murine leukemia virus (A-MuLV). The major translational product of c-Abl has been identified as a protein with tyrosine kinase activity and an SH2 domain. The c-Abl oncogene is implicated in several human leukemias including 90-95% of chronic myelocytic leukemia (CML), 20-25% of adult acute lymphoblastic leukemia (ALL) and 2-5% of pediatric ALL. c-Abl localizes to dynamic actin structures, and phosphorylates CRK and CRKL, DOK1, and other proteins controlling cytoskeleton dynamics. c-ABL potentially regulates DNA repair by activating the proapoptotic pathway when the DNA damage is too severe to be repaired.

A synthetic non-phosphopeptide derived from human c-Abl around the phosphorylation site of Tyr412 (D-T-YP-T-A)

Liquid

Immunohistochemistry (Paraffin): 1:50-1:100, Western Blot: 1:500-1:1,000

Abelson murine leukemia oncogene; Abelson murine leukemia viral (v-abl) oncogene homolog 1; abelson murine leukemia viral oncogene homolog 1; Abelson tyrosine-protein kinase 1; Abl; Abl 1 antib; ABL proto-oncogene 1, non-receptor tyrosine kinase; Abl1; ABL2; ABLL; AI325092; ARG; B30; bcr/abl; bcr/c-abl oncogene protein; c-ABL; c-abl oncogene 1, non-receptor tyrosine kinase; c-abl oncogene 1, receptor tyrosine kinase; c-ABL1; E430008G22Rik; JTK7; p150; Proto-oncogene c-Abl; proto-oncogene tyrosine-protein kinase ABL1; RP11-83J21.1; Tyrosine kinase ARG; tyrosine-protein kinase ABL1; v-abl; v-abl Abelson murine leukemia oncogene 1; v-abl Abelson murine leukemia viral oncogene 1; v-abl Abelson murine leukemia viral oncogene homolog 1